Belite Bio, Inc (BLTE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Belite Bio, Inc (BLTE) closed at USD 152.72 on 2026-10-14, a change of +64.2 % over the past year, with a market capitalization of USD 6.15B.

Belite Bio, Inc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Belite Bio, Inc key figures

Previous close

USD 152.72 (2026-10-14)

1-year change

+64.2 %

Market cap

USD 6.15B

Enterprise value

n/a

P/E ratio (trailing)

-55.70

P/E ratio (forward)

67.53

EPS (trailing)

-2.74

EPS (forward)

2.26

PEG ratio

n/a

Price to book

7.91

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.12

Employees

41

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Belite Bio, Inc and compare it with other stocks.